Renin Inhibitor Market Segmentation:
Formulation Segment Analysis
Oral tablets are leading the formulation segment and are expected to hold the greatest revenue share of 71% during the study period, till 2035. Their convenience, ease of administration, and patient adherence advantages over other dosage forms make them the preferred choice in hypertension management. Aliskiren's once-daily dosing improves compliance, particularly for extended therapy. Furthermore, the widespread availability of generics in tablet form ensures cost-effectiveness, making them suitable for mass hypertension treatment programs.
Application Segment Analysis
Under the application segment, hypertension leads the segment and is poised to hold a considerable share value by 2035. The rising prevalence of high blood pressure and increased awareness, as well as some national screening programs are the growth factors of the market. As per the WHO data in August 2021, 700 million people are living with hypertension, making it a critical health issue. Renin inhibitors, mainly for patients who are intolerant to ACE inhibitors or ARBs, are gaining traction as targeted alternatives, making hypertension a dominant segment.
Drug Type Segment Analysis
Aliskiren, the only direct renin inhibitor approved by the FDA, leads the market because it has been shown to effectively reduce blood pressure and renin activity. As per the Frontiers study in February 2023, the cost of aliskiren is USD 1.14 per day. The FDA emphasizes aliskiren as a suitable alternative in patients with contraindications against ACE inhibitors and ARBs, especially patients with hypertension. Research sponsored by the National Institutes of Health (NIH) indicates that renin inhibitors reduce systolic and diastolic blood pressure substantially relative to placebo, adding clinical value.
Our in-depth analysis of the renin inhibitor market includes the following segments:
|
Segments |
Subsegments |
|
Drug Type |
|
|
Formulation |
|
|
Distribution Channel |
|
|
Application |
|
